On May 27, 2022 Gnubiotics Sciences, a biotech company pioneering immunomodulatory glycopeptides, reported that results from its GLAAD technology program in Colorectal Cancer (CRC) will be presented in a poster presentation at the 2022 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, scheduled for June 3-7, 2022 in Chicago, Illinois (USA) (Press release, Gnubiotics Sciences, MAY 27, 2022, View Source [SID1234615171]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The poster entitled Exploiting GLAAD molecules to drive an antitumor immune response in a colorectal cancer mouse model will be presented by Yemi Adesokan, Ph.D., Gnubiotics’s Chief Executive Officer, on June 5.
"We are thrilled to present compelling pre-clinical efficacy data in colorectal cancer. These findings nicely complement previous work in melanoma presented earlier this year at AACR (Free AACR Whitepaper). Our Glycopeptides with tumor-associated Antigen and Adjuvant Delivery (GLAAD) technology is designed to drive and boost immune responses directed against various solid tumors and we are excited that the technology continues to deliver promising preclinical data, paving the way for future clinical development. With our collaborators at the University of Zurich we demonstrated that our proprietary glycopeptide candidates were capable to control tumor growth either alone or in combination with existing treatment. We are convinced that glycan-based strategies like our GLAAD approach bear great potential for safe and effective immunotherapies and respond to the urgent need for new modalities for non-responding patients that are otherwise left with few alternative treatments," stated Yemi Adesokan, Ph.D., Gnubiotics’s Chief Executive Officer.
Abstract Title: Exploiting GLAAD molecules to drive an antitumor immune response in a colorectal cancer mouse model.
Abstract Number: 2565
Session Title: Developmental Therapeutics—Immunotherapy
Session Date and Time: Sunday, June 5, 2022, 8:00 AM-11:00 AM CDT
The Poster will also be made available for browsing on the first day of the 2022 ASCO (Free ASCO Whitepaper) Annual Meeting. Viewers will have the possibility to e-mail questions and comments to the presenter.